Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis

Radiation Oncology

Harald Rief¹  Juergen Debus¹  Robert Wolf¹  Ingmar Schlampp¹  Tilman Bostel¹  Thomas Bruckner²  Christian Eisele¹  Robert Foerster¹ 

[1] Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, Heidelberg, 69120, Germany;Department of Medical Biometry, University Hospital Heidelberg, Im Neuenheimer Feld 305, Heidelberg, 69120, Germany

关键词: Local response;    Radiotherapy;    Breast cancer;    Bone metastases;    Bone density;   

Others  :  1139648
DOI  :  10.1186/s13014-015-0368-x

 received in 2015-02-12, accepted in 2015-02-24,  发布年份 2015

【 摘 要 】

Background

We designed this study to quantify the effects of radiotherapy (RT) on bone density as a local response in spinal bone metastases of women with breast cancer and, secondly, to establish bone density as an accurate and reproducible marker for assessment of local response to RT in spinal bone metastases.

Methods

We retrospectively assessed 135 osteolytic spinal metastases in 115 women with metastatic breast cancer treated at our department between January 2000 and January 2012. Primary endpoint was to compare bone density in the bone metastases before, 3 months after and 6 months after RT. Bone density was measured in Hounsfield units (HU) in computed tomography scans. We calculated mean values in HU and the standard deviation (SD) as a measurement of bone density before, 3 months and 6 months after RT. T-test was used for statistical analysis of difference in bone density as well as for univariate analysis of prognostic factors for difference in bone density 3 and 6 months after RT.

Results

Mean bone density was 194.8 HU ± SD 123.0 at baseline. Bone density increased significantly by a mean of 145.8 HU ± SD 139.4 after 3 months (p = .0001) and by 250.3 HU ± SD 147.1 after 6 months (p < .0001). Women receiving bisphosphonates showed a tendency towards higher increase in bone density in the metastases after 3 months (152.6 HU ± SD 141.9 vs. 76.0 HU ± SD 86.1; p = .069) and pathological fractures before RT were associated with a significantly higher increase in bone density after 3 months (202.3 HU ± SD 161.9 vs. 130.3 HU ± SD 129.2; p = .013). Concomitant chemotherapy (ChT) or endocrine therapy (ET), hormone receptor status, performance score, applied overall RT dose and prescription of a surgical corset did not correlate with a difference in bone density after RT.

Conclusions

Bone density measurement in HU is a practicable and reproducible method for assessment of local RT response in osteolytic metastases in breast cancer. Our analysis demonstrated an excellent local response within metastases after palliative RT.

【 授权许可】

   
2015 Foerster et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P et al.. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011; 79:965-76.
• [2]Whyne CM, Hu SS, Lotz JC. Biomechanically derived guideline equations for burst fracture risk prediction in the metastatically involved spine. J Spinal Disord Tech. 2003; 16:180-5.
• [3]Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters RS et al.. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med. 2009; 12:417-26.
• [4]Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012; 24:112-24.
• [5]Mitera G, Probyn L, Ford M, Donovan A, Rubenstein J, Finkelstein J et al.. Correlation of computed tomography imaging features with pain response in patients with spine metastases after radiation therapy. Int J Radiat Oncol Biol Phys. 2011; 81:827-30.
• [6]Wu JS, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol). 2006; 18:539-44.
• [7]Souchon R, Feyer P, Thomssen C, Fehm T, Diel I, Nitz U et al.. Clinical Recommendations of DEGRO and AGO on Preferred Standard Palliative Radiotherapy of Bone and Cerebral Metastases, Metastatic Spinal Cord Compression, and Leptomeningeal Carcinomatosis in Breast Cancer. Breast Care (Basel). 2010; 5:401-7.
• [8]Oda I, Abumi K, Lu D, Shono Y, Kaneda K. Biomechanical role of the posterior elements, costovertebral joints, and rib cage in the stability of the thoracic spine. Spine (Phila Pa 1976). 1996; 21:1423-9.
• [9]Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K et al.. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013; 21:3279-86.
• [10]Weber MH, Burch S, Buckley J, Schmidt MH, Fehlings MG, Vrionis FD et al.. Instability and impending instability of the thoracolumbar spine in patients with spinal metastases: a systematic review. Int J Oncol. 2011; 38:5-12.
• [11]Foerster R, Habermehl D, Bruckner T, Bostel T, Schlampp I, Welzel T et al.. Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival. Radiat Oncol. 2014; 9:194. BioMed Central Full Text
• [12]Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S et al.. The stability of osseous metastases of the spine in lung cancer–a retrospective analysis of 338 cases. Radiat Oncol. 2013; 8:200. BioMed Central Full Text
• [13]Schlampp I, Rieken S, Habermehl D, Bruckner T, Forster R, Debus J et al.. Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases. Strahlenther Onkol. 2014; 190:792-7.
• [14]Rief H, Petersen LC, Omlor G, Akbar M, Bruckner T, Rieken S et al.. The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - A randomized trial. Radiother Oncol. 2014; 112(1):133-9.
• [15]Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine (Phila Pa 1976). 1997; 22:239-45.
• [16]Koswig S, Budach V. Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol. 1999; 175:500-8.
• [17]Chow E, Holden L, Rubenstein J, Christakis M, Sixel K, Vidmar M et al.. Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy–a feasibility study. Radiother Oncol. 2004; 70:291-4.
• [18]Xie CM, Liu XW, Li H, Zhang R, Mo YX, Li JP et al.. Computed tomographic findings of skull base bony changes after radiotherapy for nasopharyngeal carcinoma: implications for local recurrence. J Otolaryngol Head Neck Surg. 2011; 40:300-10.
• [19]Krempien R, Huber PE, Harms W, Treiber M, Wannenmacher M, Krempien B. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer. 2003; 98:1318-24.
• [20]Ural AU, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Med Oncol. 2008; 25:350-5.
• [21]Kouloulias V, Matsopoulos G, Kouvaris J, Dardoufas C, Bottomley A, Varela M et al.. Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys. 2003; 57:143-57.
• [22]Ural AU, Avcu F, Candir M, Guden M, Ozcan MA. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res. 2006; 8:R52. BioMed Central Full Text
• [23]Algur E, Macklis RM, Hafeli UO. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys. 2005; 61:535-42.
• [24]Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J et al.. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008; 26:1051-7.
• [25]Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol. 2012; 30:3665-74.
• [26]Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC et al.. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992; 326:852-6.
• [27]Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001; 19:3306-11.